Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review

Overview

Journal Nutrients

Date 2024 Mar 13

PMID 38474784

Authors

Marta Stelmach-Mardas

Wojciech Warchol

Aleksandra Garczyk

Emilia Warchol

Jolanta Korczak

Maria Litwiniuk

Beata Brajer-Luftmann

Marcin Mardas

Affiliations

Soon will be listed here.

Abstract

The changes in body composition during androgen deprivation therapy (ADT) in patients suffering from prostate cancer (PCa) are recognized by professionals more often as biomarker for effective treatment. The aim of this study was to investigate the impact of ADT on the sarcopenia development in PCa. The following databases were used: PubMed, Embase, Web of Science and Scopus databases. Out of 2183 studies, 7 were included in this review. The fixed-effect model was used in the meta-analysis. A significant increase in SATI (Subcutaneous Adipose Tissue Index) of 0.32 (95% CI: 0.13-0.51) = 0.001, decrease in SMI (Skeletal Muscle Index) of -0.38 (95% CI: -0.57 to -0.19) < 0.0001, and SMD (Skeletal Muscle Density) of -0.46 (95% CI: -0.69 to -0.24) < 0.0001 were observed. No statistical association was visible between ADT and changes in BMI (Body Mass Index), 0.05 (95% CI: -0.18-0.28), = 0.686, and VATI (Visceral Adipose Tissue Index): 0.17 (95% CI: -0.02 to 0.37), = 0.074. In conclusion, the ADT significantly contributes to the body composition changes and sarcopenia development.

Citing Articles

Correlates and predictors of sarcopenia among men with metastatic castrate-resistant prostate cancer.

Papadopoulos E, Wong A, Law S, Zhang L, Breunis H, Emmenegger U Can Urol Assoc J. 2024; 18(12):405-412.

PMID: 39037509 PMC: 11623326. DOI: 10.5489/cuaj.8803.

References

Shao W, Zhang H, Qi H, Zhang Y . The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis. PLoS One. 2022; 17(2):e0263918. PMC: 8846498. DOI: 10.1371/journal.pone.0263918. View

Galvao D, Taaffe D, Spry N, Joseph D, Turner D, Newton R . Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2008; 12(2):198-203. DOI: 10.1038/pcan.2008.51. View

Amato M, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M . Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33(4):920-2. PMC: 2845052. DOI: 10.2337/dc09-1825. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

McGrath S, Zhao X, Steele R, Thombs B, Benedetti A . Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020; 29(9):2520-2537. PMC: 7390706. DOI: 10.1177/0962280219889080. View

Clay C, Perera S, Wagner J, Miller M, Nelson J, Greenspan S . Physical function in men with prostate cancer on androgen deprivation therapy. Phys Ther. 2007; 87(10):1325-33. DOI: 10.2522/ptj.20060302. View

Korczak J, Mardas M, Litwiniuk M, Bogdanski P, Stelmach-Mardas M . Androgen Deprivation Therapy for Prostate Cancer Influences Body Composition Increasing Risk of Sarcopenia. Nutrients. 2023; 15(7). PMC: 10096521. DOI: 10.3390/nu15071631. View

de Pablos-Rodriguez P, Del Pino-Sedeno T, Infante-Ventura D, de Armas-Castellano A, Backhaus M, Ferrer J . Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review. J Clin Med. 2023; 12(1). PMC: 9821501. DOI: 10.3390/jcm12010057. View

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

10.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

11.

Griggs R, Kingston W, Jozefowicz R, Herr B, Forbes G, Halliday D . Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol (1985). 1989; 66(1):498-503. DOI: 10.1152/jappl.1989.66.1.498. View

12.

Smith M . Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004; 63(4):742-5. DOI: 10.1016/j.urology.2003.10.063. View

13.

Sheikhbahaei S, Reyes D, Rowe S, Pienta K . CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer. Prostate. 2020; 81(2):127-134. PMC: 7839584. DOI: 10.1002/pros.24088. View

14.

Basaria S, Lieb 2nd J, Tang A, DeWeese T, Carducci M, Eisenberger M . Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002; 56(6):779-86. DOI: 10.1046/j.1365-2265.2002.01551.x. View

15.

Storer T, Miciek R, Travison T . Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012; 14(2):204-21. PMC: 3735097. DOI: 10.1038/aja.2011.104. View

16.

McGovern J, Dolan R, Horgan P, Laird B, McMillan D . Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 2021; 12(6):1408-1417. PMC: 8718024. DOI: 10.1002/jcsm.12831. View

17.

Kimura Y, Yamada M, Ohji S, Ishiyama D, Nishio N, Otobe Y . Presence of sarcopenic obesity and evaluation of the associated muscle quality in Japanese older men with prostate cancer undergoing androgen deprivation therapy. J Geriatr Oncol. 2019; 10(5):835-838. DOI: 10.1016/j.jgo.2019.03.017. View

18.

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

19.

Alibhai S, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I . Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol. 2010; 28(34):5038-45. DOI: 10.1200/JCO.2010.29.8091. View

20.

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G . Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9):1119-1134. DOI: 10.1016/j.annonc.2020.06.011. View